Seymur Gahramanov Selected Research

Ferrosoferric Oxide (Magnetite)

1/2016	Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations.
8/2014	Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
7/2013	Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.
5/2013	High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle.
3/2013	Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
8/2012	Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
4/2012	Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study.
12/2011	Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
10/2011	Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
2/2011	Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seymur Gahramanov Research Topics

Disease

11	Neoplasms (Cancer) 07/2014 - 04/2009
4	Glioblastoma (Glioblastoma Multiforme) 08/2014 - 02/2011
3	Brain Neoplasms (Brain Tumor) 07/2014 - 01/2011
2	Neoplasm Metastasis (Metastasis) 01/2016 - 10/2012
2	Central Nervous System Diseases (CNS Diseases) 01/2016 - 01/2010
2	Glioma (Gliomas) 10/2010 - 04/2009
1	Pathologic Processes 01/2018
1	Anaphylaxis (Anaphylactic Shock) 01/2017
1	Meningioma (Meningiomas) 01/2016
1	Pneumonia (Pneumonitis) 07/2014
1	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 07/2014
1	Inflammation (Inflammations) 07/2013
1	Demyelinating Diseases (Demyelinating Disease) 07/2013
1	Lymphoma (Lymphomas) 07/2013
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 07/2013
1	Nephrogenic Fibrosing Dermopathy 07/2013
1	Central Nervous System Neoplasms 05/2013
1	Breast Neoplasms (Breast Cancer) 10/2012
1	Intracranial Aneurysm (Cerebral Aneurysm) 04/2012
1	Aneurysm (Aneurysms) 04/2012
1	Renal Insufficiency (Renal Failure) 10/2011
1	Oligodendroglioma 01/2010
1	Thrombocytopenia (Thrombopenia) 01/2010

Drug/Important Bio-Agent (IBA)

12	Ferrosoferric Oxide (Magnetite)FDA Link 01/2016 - 04/2009
6	Contrast MediaIBA 01/2017 - 01/2010
3	GadoliniumIBA 01/2016 - 12/2011
3	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 07/2013 - 04/2009
3	gadoteridol (Prohance)FDA Link 03/2013 - 02/2011
2	Temozolomide (Temodar)FDA LinkGeneric 07/2014 - 01/2010
2	IntegrinsIBA 10/2012 - 01/2011
2	intetumumabIBA 10/2012 - 01/2011
2	gadodiamide (Omniscan)FDA Link 12/2011 - 04/2009
2	Bevacizumab (Avastin)FDA Link 01/2011 - 04/2009
1	Oxygen (Dioxygen)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 03/2013
1	ferric ferrocyanide (Prussian blue)FDA Link 04/2012
1	IronIBA 04/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2011
1	Monoclonal AntibodiesIBA 01/2011
1	Indicators and Reagents (Reagents)IBA 10/2010
1	etoposide phosphate (Etopophos)FDA Link 01/2010
1	Carboplatin (JM8)FDA LinkGeneric 01/2010
1	Melphalan (Alkeran)FDA LinkGeneric 01/2010
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2009

Therapy/Procedure

3	Chemoradiotherapy 08/2014 - 02/2011
1	Radiotherapy 03/2013
1	Therapeutics 12/2011
1	Aftercare (After-Treatment) 01/2011
1	Drug Therapy (Chemotherapy) 01/2010